These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 9138997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
    Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J.
    Int J Biol Markers; 2007; 22(3):172-80. PubMed ID: 17922459
    [Abstract] [Full Text] [Related]

  • 3. CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.
    Ismail MA, Rotmensch J, Mercer LJ, Block BS, Salti GI, Holt JA.
    J Reprod Med; 1994 Jul; 39(7):510-2. PubMed ID: 7966039
    [Abstract] [Full Text] [Related]

  • 4. CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.
    Carico E, Chicchirichi R, Atlante M, Giovagnoli M, Vecchione A.
    Anticancer Res; 1995 Jul; 15(2):631-4. PubMed ID: 7763049
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese K, Stieber P, Burges A.
    Clin Chem Lab Med; 2009 Jul; 47(5):537-42. PubMed ID: 19317653
    [Abstract] [Full Text] [Related]

  • 6. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
    Zaucha R, Kobierska A.
    Przegl Lek; 1995 Jul; 52(2):51-3. PubMed ID: 7784616
    [Abstract] [Full Text] [Related]

  • 7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
    Sevinc A, Camci C, Turk HM, Buyukberber S.
    Oncology; 2003 Jul; 65(1):1-6. PubMed ID: 12837976
    [Abstract] [Full Text] [Related]

  • 8. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
    Schneider D, Halperin R, Langer R, Bukovsky I, Herman A.
    Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
    [Abstract] [Full Text] [Related]

  • 9. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.
    Onsrud M, Shabana A, Austgulen R, Nustad K.
    Gynecol Oncol; 1995 May; 57(2):183-7. PubMed ID: 7729731
    [Abstract] [Full Text] [Related]

  • 10. Tissue quantification of CA 125 in epithelial ovarian cancer.
    de la Cuesta R, Maestro ML, Solana J, Vidart JA, Escudero M, Iglesias E, Valor R.
    Int J Biol Markers; 1999 May; 14(2):106-14. PubMed ID: 10399630
    [Abstract] [Full Text] [Related]

  • 11. Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer.
    Boran N, Kayikçioğlu F, Yalvaç S, Tulunay G, Ekinci U, Köse MF.
    Gynecol Obstet Invest; 2000 May; 49(4):272-4. PubMed ID: 10828712
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer.
    Yüce K, Baykal C, Genç C, Al A, Ayhan A.
    Eur J Gynaecol Oncol; 2001 May; 22(3):228-32. PubMed ID: 11501779
    [Abstract] [Full Text] [Related]

  • 13. CA 125 in peritoneal fluid: reliable values at high dilutions.
    Barbati A, Anceschi MM, Di Renzo GC, Cosmi EV.
    Obstet Gynecol; 1992 Jun; 79(6):1011-5. PubMed ID: 1579297
    [Abstract] [Full Text] [Related]

  • 14. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D.
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [Abstract] [Full Text] [Related]

  • 15. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
    Porsbjerg CM, Sørensen JB, Lund BA.
    Ugeskr Laeger; 1998 Feb 09; 160(7):995-1000. PubMed ID: 9477746
    [Abstract] [Full Text] [Related]

  • 16. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
    Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M.
    Gynecol Oncol; 2000 May 09; 77(2):254-7. PubMed ID: 10785474
    [Abstract] [Full Text] [Related]

  • 17. [Role of second-look surgery in treatment of ovarian neoplasms].
    Markowska J, Szewierski Z, Roszak A, Niecewicz R.
    Ginekol Pol; 1996 Apr 09; 67(4):200-4. PubMed ID: 8846933
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
    Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins RV, DePriest PD, Ueland FR, Kryscio RJ, Whitley RJ, Nagell Jv.
    Gynecol Oncol; 2003 May 09; 89(2):233-5. PubMed ID: 12713985
    [Abstract] [Full Text] [Related]

  • 19. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, Erten O.
    Gynecol Oncol; 2002 Apr 09; 85(1):108-13. PubMed ID: 11925128
    [Abstract] [Full Text] [Related]

  • 20. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ, Liou WS, Liu RS, Hu C, Tsay DG, Liu CB.
    Cancer Biother Radiopharm; 2011 Apr 09; 26(2):175-81. PubMed ID: 21510748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.